Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6.
Photoreceptor cGMP phosphodiesterase (PDE6) is the central enzyme in the visual transduction cascade. The PDE6 catalytic subunit contains a catalytic domain and regulatory GAF domains. Unlike most GAF domain-containing cyclic nucleotide phosphodiesterases, little is known about direct allosteric communication of PDE6. In this study, we demonstrate for the first time direct, inter-domain allosteric communication between the GAF and catalytic domains in PDE6. The binding affinity of PDE6 for pharmacological inhibitors or for the C-terminal region of the inhibitory gamma subunit (Pgamma), known to directly inhibit PDE6 catalysis, was increased approximately 2-fold by ligands binding to the GAF domain. Binding of the N-terminal half of Pgamma to the GAF domains suffices to induce this allosteric effect. Allosteric communication between GAF and catalytic domains is reciprocal, in that drug binding to the catalytic domain slowed cGMP dissociation from the GAF domain. Although cGMP hydrolysis was not affected by binding of Pgamma1-60, Pgamma lacking its last seven amino acids decreased the Michaelis constant of PDE6 by 2.5-fold. Pgamma1-60 binding to the GAF domain increased vardenafil but not cGMP affinity, indicating that substrate- and inhibitor-binding sites do not totally overlap. In addition, prolonged incubation of PDE6 with vardenafil or sildenafil (but not 3-isobutyl-1-methylxanthine and zaprinast) induced a distinct conformational change in the catalytic domain without affecting the binding properties of the GAF domains. We conclude that although Pgamma-mediated regulation plays the dominant role in visual excitation, the direct, inter-domain allosteric regulation described in this study may play a feedback role in light adaptational processes during phototransduction.
Zhang
Xiu-Jun
XJ
Department of Biochemistry and Molecular Biology, University of New Hampshire, Durham, New Hampshire 03824, USA.
Cahill
Karyn B
KB
Elfenbein
Arye
A
Arshavsky
Vadim Y
VY
Cote
Rick H
RH
D000495:Allosteric Site; D000818:Animals; D020134:Catalytic Domain; D002417:Cattle; D006152:Cyclic GMP / Q000378:metabolism; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6 / Q000737:chemistry / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D008968:Molecular Conformation; D010879:Piperazines / Q000494:pharmacology; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D011687:Purines / Q000494:pharmacology; D012160:Retina / Q000378:metabolism; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology; D000069058:Vardenafil Dihydrochloride
D007093:Imidazoles; D008024:Ligands; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068677:Sildenafil Citrate; D054707:Cyclic Nucleotide Phosphodiesterases, Type 6; D006152:Cyclic GMP
FEBS Lett. 1988 Jul 18;234(2):287-90
2455657
Nat Genet. 1994 May;7(1):64-8
8075643
Biochem J. 1992 Feb 1;281 ( Pt 3):637-43
1311170
Biochem J. 1992 Apr 1;283 ( Pt 1):273-9
1314566
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5407-12
8643588
Mol Pharmacol. 2008 Jan;73(1):104-10
17959709
J Biol Chem. 2006 Jun 2;281(22):15412-22
16595671
Mol Pharmacol. 2004 Jul;66(1):144-52
15213306
J Biol Chem. 2005 Apr 1;280(13):12585-92
15668239
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3060-6
16123402
J Biol Chem. 1992 Dec 5;267(34):24501-7
1332960
Structure. 2004 Dec;12(12):2233-47
15576036
J Biol Chem. 2000 Dec 29;275(52):41258-62
11024033
Proc Natl Acad Sci U S A. 1982 Jun;79(12):3702-6
6285360
Mol Pharmacol. 2003 Jun;63(6):1364-72
12761347
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1505-10
18230733
Vision Res. 2006 Mar;46(6-7):860-8
16256165
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5137-52
17122096
Biochemistry. 2003 Mar 25;42(11):3305-10
12641462
Methods Mol Biol. 2005;307:141-54
15988061
J Biol Chem. 2001 Jul 20;276(29):27527-34
11375400
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4845-9
8197145
Methods Mol Biol. 2005;307:125-40
15988060
J Biol Chem. 1980 Jan 25;255(2):620-6
6153179
J Biol Chem. 1980 Dec 10;255(23):11619-24
6254976
J Biol Chem. 1983 Oct 25;258(20):12526-33
6313664
Eur J Biochem. 2000 May;267(9):2760-7
10785399
J Biol Chem. 2000 Jul 7;275(27):20572-7
10787404
Hum Mutat. 2007 Mar;28(3):243-54
17044014
Front Biosci. 2005 May 01;10:1191-204
15769618
J Biol Chem. 1999 Jun 25;274(26):18813-20
10373499
Mol Pharmacol. 2004 Feb;65(2):267-78
14742667
J Biol Chem. 1999 Oct 8;274(41):29038-41
10506154
Methods Enzymol. 2000;315:646-72
10736732
J Biol Chem. 2004 Mar 26;279(13):13095-101
14668322
J Biol Chem. 1995 Jun 2;270(22):13210-5
7768919
Vision Res. 2004;44(21):2437-44
15358079
Int J Impot Res. 2004 Jun;16 Suppl 1:S28-33
15224133
Biochem J. 1999 Jun 15;340 ( Pt 3):863-9
10359674
J Biol Chem. 2004 Nov 12;279(46):48143-51
15331594
Trends Biochem Sci. 1997 Dec;22(12):458-9
9433123
Methods. 1998 Jan;14(1):93-104
9500861
J Gen Physiol. 1998 Jan;111(1):39-51
9417133
J Biol Chem. 1998 Mar 6;273(10):5557-65
9488681
EMBO J. 2003 Feb 3;22(3):469-78
12554648
Anal Biochem. 1985 Oct;150(1):76-85
3843705
J Pharmacol Exp Ther. 2007 Nov;323(2):730-7
17690252
J Biol Chem. 2002 Feb 1;277(5):3310-7
11723116
J Biol Chem. 2006 Feb 3;281(5):2841-6
16330539
J Biol Chem. 1982 Feb 25;257(4):1973-9
6276403
J Biol Chem. 1990 Sep 5;265(25):14964-70
1697584
J Biol Chem. 2002 Dec 6;277(49):47581-7
12359732
Annu Rev Physiol. 2002;64:153-87
11826267
Mol Cell. 2004 Jul 23;15(2):279-86
15260978
J Biol Chem. 2006 Jul 28;281(30):21469-21479
16735511
Mol Pharmacol. 1999 Jul;56(1):124-30
10385692
J Cell Biol. 2003 Mar 3;160(5):719-27
12604588